GlycoMimetics to Present GMI-1271 Research Findings at AACR

Document technical information

Format pdf
Size 13.8 kB
First found May 22, 2018

Document content analysis

Category Also themed
not defined
no text concepts found





March 5, 2014
GlycoMimetics to Present GMI-1271 Research Findings at AACR Annual Meeting 2014
- Data on E-selectin antagonist to be highlighted with three posters GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) announced today plans to present findings
from research studies of its E-Selectin antagonist (GMI-1271) with three posters at the American Association for Cancer
Research (AACR) Annual Meeting 2014. The posters will focus on the novel glycomimetic drug candidate's potential as a
treatment beyond hematological cancers to solid tumors (i.e., for breast cancer metastasis) as well as for its use in improving
chemotherapy treatment. The AACR Annual Meeting 2014 will be held April 5-9 at the San Diego Convention Center.
"Our preclinical research findings substantiate the focus on E-selectin as a potential target for blood-related malignancies and
for solid tumors that have metastasized," said John Magnani, Ph.D., GlycoMimetics Vice President and Chief Scientific Officer.
"We are excited to have the opportunity to present our findings to the cancer research community members who will be in
attendance at the meeting, and look forward to soon initiating our first clinical program with GMI-1271 for the treatment of acute
myeloid leukemia (AML)."
GMI-1271 is currently in preclinical studies for blood cancers and other cancers that are associated with elevated risk of
metastasis and thrombosis. GlycoMimetics anticipates initiating a Phase 1 trial of GMI-1271 in healthy volunteers in the second
quarter of 2014. The company is initially exploring the clinical use of the drug to treat AML.
Following are the specifics of the abstracts, including session times and locations:
"Exploration of a Potent E-selectin Antagonist (GMI-1271) As a Potential Novel Therapeutic for Treating Breast Cancer
Metastasis to the Bone and Lung." [Poster Session: Therapeutic Approaches for Metastatic Tumors, Abstract Number
4039, Tuesday, Apr 08, 2014, 1:00 PM - 5:00 PM, Hall A-E, Poster Section 7, Poster Board Number 18]
"A Small Molecule Glycomimetic Antagonist of E-selectin (GMI-1271) Prevents Pancreatic Tumor Metastasis and Offers a
Novel Treatment for Improved Efficacy of Chemotherapy." [Poster Session: Biologic Therapy 3, Abstract Number 4503,
Tuesday, Apr 08, 2014, 1:00 PM - 5:00 PM, Hall A-E, Poster Section 29, Poster Board Number 13]
"Breast Cancer Cells Metastasize to Bone Through E-selectin+ Vascular Gateways." [Poster Session: Circulating and
Disseminated Tumor Cells as Predictors of Tumor Metastasis, Abstract Number 4831, Wednesday, Apr 09, 2014, 8:00
AM -12:00 PM, Hall A-E, Poster Section 1, Poster Board Number 19]
The meeting abstracts are available at AACR's website.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics
are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in
carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug
candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and
This press release contains forward-looking statements regarding GlycoMimetics' planned activities with respect to the clinical
development of GMI-1271. Actual results may differ materially from those in these forward-looking statements. For a further
description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk
factors described in the Company's Registration Statement on Form S-1 that was originally filed with the U.S. Securities and
Exchange Commission on October 4, 2013, and the amendments thereto, including those factors discussed under the caption
"Risk Factors" in such filings. Forward-looking statements speak only as of the date of this release, and GlycoMimetics
undertakes no obligation to update or revise these statements, except as may be required by law.
GlycoMimetics, Inc.
Brian Hahn, 240-243-1207
[email protected]
Source: GlycoMimetics, Inc.
News Provided by Acquire Media

Similar documents


Report this document